Any current/future new fundraising through debt or equity?

The company has not indicated any current or planned fundraising through debt or equity. Expansion plans for new hub centers in Pune, Kolkata, and adjacent geographies are being funded through internal accruals. The management emphasized strong cash reserves (INR212 crores as of Q1 FY'25) to support growth. There is no mention of external capital raising, implying reliance on internal resources for ongoing and planned expansions.

Any current/future capex/capital investment/strategic investment?

The company has finalized leases for nine new hub locations across home states, Pune, and West Bengal, scheduled to start operations within the next 12 to 18 months. Capex per typical hub ranges from INR 12 to 14 crores; for advanced hubs with 3 Tesla MRI and high-end cardiac CT, capex may be INR 18 to 19 crores. Expansion in new geographies (Pune, Kolkata, adjacent markets) will be funded from internal accruals. The focus is on opening hubs in FY'25, with spokes expected to follow from FY'26 after hubs mature. Equipment additions, including advanced diagnostic devices like 3.0 Tesla MRI and 1

Future growth expectations in sales/revenue/volumes?

Vijaya Diagnostic Centre has seen robust organic growth, with a 20% year-on-year increase excluding PH Pune, driven by volume growth of 20% and footfall growth of 17%. Existing centers (as of FY22) continue growing at double-digit rates (~12-13%) with room for further growth over the next 1-2 years. New centers added in FY23 and FY24 contribute to accelerated growth, with newer hubs delivering higher patient footfall growth (around 17% in the recent quarter). The company expects the double-digit volume and revenue growth to continue, supported by both existing and new centers. Expansion focus

Future growth expectations in earnings/operating earnings/profits/EPS?

Vijaya Diagnostics expects continued robust volume growth, supported by both existing and new centers, with existing centers growing at ~12-13% and new centers contributing higher growth. Management anticipates sustaining strong double-digit revenue growth driven by organic growth and capacity additions. EBITDA margins are expected to remain stable around 39-40%, despite aggressive expansion and new hub additions, due to quick breakeven of new centers (usually within 1 year). Operating profits and PAT growth align with revenue growth, supported by operational efficiencies and a healthy balance

Vijaya Diagnost.Q1 FY25Healthcare Services

Vijaya Diagnost. Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,428P/E: 83.2Market Cap: ₹15.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Vijaya Diagnostic Centre has seen robust organic growth, with a 20% year-on-year increase excluding PH Pune, driven by volume growth of 20% and footfall growth of 17%.
Existing centers (as of FY22) continue growing at double-digit rates (~12-13%) with room for further growth over the next 1-2 years.
New centers added in FY23 and FY24 contribute to accelerated growth, with newer hubs delivering higher patient footfall growth (around 17% in the recent quarter).
The company expects the double-digit volume and revenue growth to continue, supported by both existing and new centers.
Expansion focus remains on hubs, especially in Pune and Kolkata, with plans to add 9 new hubs in 12-18 months to sustain growth.
Long-term growth will rely on both organic expansion in existing centers and adding new capacities in newer geographies.
EBITDA margins expected to remain stable around 39-40% despite expansion.

Margin guidance

Category 3

Vijaya Diagnostics expects continued robust volume growth, supported by both existing and new centers, with existing centers growing at ~12-13% and new centers contributing higher growth.
Management anticipates sustaining strong double-digit revenue growth driven by organic growth and capacity additions.
EBITDA margins are expected to remain stable around 39-40%, despite aggressive expansion and new hub additions, due to quick breakeven of new centers (usually within 1 year).
Operating profits and PAT growth align with revenue growth, supported by operational efficiencies and a healthy balance sheet.
Earnings per share (EPS) growth is expected to track the overall profit growth, with recent quarters showing strong profitability (20% PAT margin).
Expansion into new geographies (Pune, Kolkata, etc.) is expected to underpin long-term growth without material margin dilution.

See what Vijaya Diagnost. management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company has not indicated any current or planned fundraising through debt or equity.
Expansion plans for new hub centers in Pune, Kolkata, and adjacent geographies are being funded through internal accruals.
The management emphasized strong cash reserves (INR212 crores as of Q1 FY'25) to support growth.
There is no mention of external capital raising, implying reliance on internal resources for ongoing and planned expansions.

Order book

The document does not explicitly mention any current or expected order book or pending orders for Vijaya Diagnostic Centre Limited. However, key relevant points include: - The company has signed leases for nine new hub locations across Pune, Kolkata, and adjacent geographies, scheduled to commence operations over the next 12 to 18 months. - Expansion is progressing with new hubs and centers planned, including a new hub facility in Ongole starting August 2024. - The expansion plan is funded through internal accruals, indicating no external orders or contracts referenced. - The company is focusing on steady addition of capacity via hubs and spokes to sustain double-digit growth. - There is no specific mention of pending orders or an order backlog as would be typically relevant in manufacturing or project-based businesses. Hence, there is no disclosed "order book" or "pending orders" from the available information.

See what Vijaya Diagnost. management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has finalized leases for nine new hub locations across home states, Pune, and West Bengal, scheduled to start operations within the next 12 to 18 months.
Capex per typical hub ranges from INR 12 to 14 crores; for advanced hubs with 3 Tesla MRI and high-end cardiac CT, capex may be INR 18 to 19 crores.
Expansion in new geographies (Pune, Kolkata, adjacent markets) will be funded from internal accruals.
The focus is on opening hubs in FY'25, with spokes expected to follow from FY'26 after hubs mature.
Equipment additions, including advanced diagnostic devices like 3.0 Tesla MRI and 160-slice cardiac CT, are part of the new hubs.
No material drag expected on overall margins from expansion; EBITDA margins around 39%-40% are sustainable despite aggressive growth plans.

Track Vijaya Diagnost. — get its next earnings analysis in your feed

How does Vijaya Diagnost. rank vs peers in Healthcare Services?

Pro feature

ThisVijaya Diagnost.

Rev 3Mar 3

See where Vijaya Diagnost. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Vijaya Diagnost. rank in Healthcare Services?

Compare Vijaya Diagnost. against every Healthcare Services company (Q1 FY25) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Vijaya Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Vijaya Diagnost. Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Vijaya Diagnost. rank in Healthcare Services?

Continue your research

What Vijaya Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season